Brexit means Brexit, but what of pharmacovigilance?

Abstract

While uncertainty remains over exactly how the UK's exit from the European Union will pan out, there is little doubt that there will be disruption, at least in the short term, for the pharmaceutical industry. Issues surrounding the potential implications of Brexit for the medicines regulatory system, and for pharmacovigilance in particular, were discussed at a recent meeting in London, organised by the Drug Safety Research Unit. Steve Titmarsh reports.